In-Licensing Mesalazine from Ferring
First written in FY2022-Q1. 1 of 3 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1Switch in mesalazine agreementAnnual report
「Newly executed material agreement Sales agreement (license-in) Pentasa Ferring Switzerland 2025 From the contract date until 31 December 2031」
While the 2021 mesalazine license-in agreement with Ferring was terminated, a new 2025 sales agreement (license-in) was executed for Pentasa. - FY2022-Q2RestatedAnnual report
「Kyorin Pharmaceutical Co., Ltd. (consolidated subsidiary) Mesalazine Ferring Private Singapore Royalties at a fixed rate / supply price 2021 From the contract date until 31 December 2031」
The company continues to disclose the mesalazine license-in agreement with Ferring Private and its term through 31 December 2031. - FY2022-Q1First statedAnnual report
「In-licensing from a foreign company; contracting company: KYORIN Pharmaceutical Co.,Ltd. (consolidated subsidiary); product: mesalazine; counterparty: Ferring Private; country: Singapore; consideration: royalties at a specified rate / supply price; contract year: 2021; term: from the date of execution through 31 December 2031.」
The Group entered into an in-licensing agreement with Ferring Private for mesalazine, with the term running through 31 December 2031 and consideration consisting of royalties and a supply price.